This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...

11 These mechanisms will be important to more fully elucidate to inform whether targeting central or peripheral GLP-1 receptors is necessary and thus whether higher CNS drug concentrations are needed.

As earlier outlined, short-term studies in animals and humans have shown GLP-1 to have some direct vasorelaxation action ... in patients receiving GLP1-RA therapy. There are no published studies ...

Researchers found that GLP-1 RA use was not associated with an increased risk for thyroid cancer compared with use of DPP-4i. HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...